Private Market View

Resonant Therapeutics

Houston, TX · Founded 2014 · Privately Held (backing)

PA Mark · $/share
$10
Sep 2026
Implied valuation
$17.3M
Total raised
$6.1M
Last round
Seed Round
Oct 2021

Key facts

as of Sep 2026
  • Resonant Therapeutics’s last known valuation is $17.3M (Oct 2021).
  • It has raised $6.1M across 1 recorded rounds; the latest was Seed Round ($2.5M) in Oct 2021.
  • Notable investors include Johnson & Johnson Innovation - JLABS, Mercury Fund, Innovation Partnerships, Urban Capital Network, MINTS (Michigan Investment in New Technology Startups) — 7 tracked in total.
  • 1 institutional filer reports fund marks on Resonant Therapeutics across 6 filings.
  • Resonant Therapeutics has filed 1 Form D with the SEC, most recently Oct 2021 ($2.5M sold to 16 investors).
  • Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence
~$10per share
as of Sep 2026 · the exact daily mark is a member feature
Composed from 1 inputs:N-PORT marks 100%
See the platform prints behind this mark →
Free account
See the evidence behind this price
  • ·Post-money valuations for all 1 rounds
  • ·The complete investor list — 7 names
  • ·Watchlist + deal alerts for Resonant Therapeutics
Create free account
No card required

Recorded secondary trades

No prints on record

No secondary trades in Resonant Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

1 filers · latest Oct 2025

1 SEC-registered fund reported 6 fair-value marks on Resonant Therapeutics between Apr 2025 and Oct 2025. Filer-level marks and implied $/share are available to Pro members.

Unlock 6 fund marks

Funding rounds

1 rounds
Oct 2021Seed Round$2.5MSEC filing▮
Full funding history →

About Resonant Therapeutics

Developer of a drug discovery platform designed to help pharma clients expand their drug discovery pipeline. The company's platform focuses on the tumour microenvironment and data science to identify novel tumour-selective targets and anti-tumour antibodies, enabling researchers to identify and accelerate therapeutic and target discovery against cancers.

Sector
Healthcare
HQ
Houston, TX, United States
Founded
2014
Employees
5
Ownership
Privately Held (backing)